Latent Labs Emerges with $50M to Revolutionize Drug Discovery Using AI

Latent Labs Emerges from Stealth with Ambitious AI-Driven Protein Design Goals

Latent Labs, a startup at the intersection of artificial intelligence and biotechnology, has emerged from stealth mode with a substantial $50 million in funding 1

1

2

2

3

3

4

4

. Founded by Dr. Simon Kohl, a former co-lead at Google DeepMind's protein design team and senior research scientist on the Nobel Prize-winning AlphaFold2 project, Latent Labs aims to push the boundaries of generative biology 2

2

.

Funding and Investor Support

The company's $50 million funding includes a previously undisclosed $10 million seed round and a fresh $40 million Series A 3

3

. The investment was co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC 1

1

2

2

. Notable angel investors include Google's chief scientist Jeff Dean, Cohere founder Aidan Gomez, and ElevenLabs founder Mati Staniszewski 2

2

3

3

.

Revolutionary Approach to Protein Design

Latent Labs is developing foundation AI models that go beyond predicting protein shapes to generating entirely new protein designs from scratch 1

1

. The company is focusing its efforts on two types of proteins: antibodies and enzymes, which are crucial in immune system function and pharmaceutical manufacturing, respectively 1

1

.

Business Model and Partnerships

Unlike many AI drug discovery startups, Latent Labs does not plan to develop its own therapeutic candidates. Instead, the company aims to partner with biotech and pharmaceutical companies, offering its AI platform as a service to accelerate and de-risk early-stage R&D 3

3

4

4

. This approach allows Latent Labs to potentially impact a broader range of drug discovery programs across the industry.

Technology and Infrastructure

Latent Labs is building custom software to speed up its AI model development, with a particular focus on automating the hyperparameter search phase 1

1

. The company is also establishing wet labs in both London and San Francisco to test the proteins developed by its AI models and generate research data for model fine-tuning 1

1

3

3

.

Vision for the Future of Drug Discovery

Simon Kohl envisions a future where biology becomes "programmable," significantly reducing reliance on wet lab experiments 3

3

. The ultimate goal is to enable researchers to computationally create new therapeutic molecules with desired properties "at the push of a button," potentially revolutionizing the drug discovery process 3

3

4

4

.

Industry Context and Competition

Latent Labs enters a competitive field, with many startups and established companies applying AI to drug discovery. However, its focus on generative AI for protein design and its service-oriented business model set it apart 4

4

. The company's approach aligns with the growing trend of AI application in life sciences, which saw $8 billion in venture capital investments in Europe alone in 2024 2

2

.

As Latent Labs continues to develop its technology and expand its team, the biotech and pharmaceutical industries will be watching closely to see if this new venture can deliver on its promise to accelerate drug discovery and potentially transform the way new medicines are developed.